Celsion Corp. (NASDAQ:CLSN) Chairman Michael H. Tardugno purchased 10,000 shares of the company’s stock in a transaction that occurred on Friday, October 7th. The stock was acquired at an average cost of $1.14 per share, with a total value of $11,400.00. Following the transaction, the chairman now directly owns 143,021 shares of the company’s stock, valued at $163,043.94. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Shares of Celsion Corp. (NASDAQ:CLSN) traded down 2.56% during mid-day trading on Tuesday, reaching $1.14. 32,713 shares of the company’s stock traded hands. Celsion Corp. has a 12 month low of $1.04 and a 12 month high of $2.31. The stock’s market cap is $29.42 million. The firm has a 50 day moving average price of $1.23 and a 200-day moving average price of $1.34.

Celsion Corp. (NASDAQ:CLSN) last announced its earnings results on Monday, August 15th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.02. Celsion Corp. had a negative net margin of 3,966.14% and a negative return on equity of 103.07%. On average, analysts predict that Celsion Corp. will post ($0.83) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Celsion Corp. (NASDAQ:CLSN)

Several research analysts recently issued reports on the stock. Maxim Group reissued a “buy” rating and issued a $4.00 price target on shares of Celsion Corp. in a research report on Thursday, September 15th. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of Celsion Corp. in a research note on Tuesday, July 12th.

A hedge fund recently raised its stake in Celsion Corp. stock. Sabby Management LLC increased its stake in Celsion Corp. (NASDAQ:CLSN) by 7,986.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,519,365 shares of the company’s stock after buying an additional 1,500,576 shares during the period. Sabby Management LLC owned about 6.48% of Celsion Corp. worth $1,930,000 as of its most recent filing with the SEC. Institutional investors own 15.19% of the company’s stock.

About Celsion Corp.

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

5 Day Chart for NASDAQ:CLSN

Receive News & Stock Ratings for Celsion Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corp. and related stocks with our FREE daily email newsletter.